Category: 8. Health

Between November 2019 and July 2021, 201 women were enrolled in the study. These included 98 kidney transplant recipients, 93 liver transplant recipients, and ten patients who received simultaneous kidney and liver transplantation. 65.2% of patients knew they were at increased risk for genitoanal cancers, and 77.6% knew cervical screening could reduce cancer risk. In addition, most patients (92.5%) reported regularly taking advantage of the cervical screening offer.

HrHPV prevalence

The baseline characteristics of the participants are shown in Table 1, which compares hrHPV positive and negative patients. Overall, 32 out of 201 (15.9%) patients tested positive for hrHPV at the cervical site. The anal hrHPV prevalence was 20.3% (40/197). No significant difference in cervical hrHPV prevalence was found between kidney and liver transplanted patients (see Table 2). The median age was 52 years (median 18–78), with cervical hrHPV-positive patients being, on average, eight years younger (p = 0.029). HrHPV prevalence declined with increasing age as shown in Fig. 1. However, the differences in cervical hrHPV prevalence across age groups were not statistically significant (p = 0.068), whereas anal hrHPV prevalence did show a significant difference across age groups (p = 0.038). When comparing individuals aged ≤ 45 years to those > 45 years, anal hrHPV prevalence was significantly higher in the younger age group (p = 0.020). In contrast, cervical hrHPV prevalence showed a non-significant trend towards higher rates in the younger group (p = 0.078).The median body mass index (BMI) was 23.4 in the cervical hrHPV-negative group and 21.4 in the cervical hrHPV-positive group (p = 0.030).

Immunosuppressive treatment

Overall, 97.5% of the patients were currently taking immunosuppressants, with most (75%) being on a calcineurin inhibitor (CNI) based immunosuppressive regimen consisting of more than two drugs. A comparison of immunosuppression and HPV risk factors is shown in Table 1. Neither the number of immunosuppressants nor the type of immunosuppression was significantly associated with hrHPV infection. Other transplant-specific variables, such as duration of immunosuppressive treatment, pretransplant immunosuppressant use, or graft rejections, did not correlate with hrHPV infection. A comparison of kidney and liver transplant recipients showed differences in immunosuppressive therapy (see Table 2). Compared to liver transplants, more kidney recipients took at least two immunosuppressants and had higher induction therapy rates (85.5% vs. 37%). However, cervical hrHPV prevalence showed no significant difference. Additionally, risk factors like sexual partners and age at first intercourse didn’t differ between kidney and liver recipients.

Risk factors associated with increased HPV prevalence in the general population, i.e. sexual behaviour and younger age, are confirmed in transplanted patients in a multivariable logistic regression model, with adjusting for transplantation, nicotine use and age of first intercourse (see Table 3). HrHPV-positive women were, on average, one year younger at the time of first sexual intercourse (p = 0.025) and had more than twice as many sexual partners as HPV- negative patients (p < 0.001). Likewise, the number of sexual partners since the first transplant was significantly higher among hrHPV-positive patients (p < 0.001).

HPV vaccination

In total, 12.4% (25/201) of patients had prior HPV vaccination. Among them, 80% (20/25) were under 30, while only 2.9% (5/173) of those over 30 were vaccinated (p < 0.0001). Most patients were vaccinated before their first sexual intercourse (17/25), and six were vaccinated before transplantation. The number of vaccinated patients was higher among HPV-positive patients compared with HPV-negative patients (see Table 1). Three HPV-positive women were vaccinated after their first sexual intercourse and six after their transplantation.

Follow-up

The participation rate in the follow-up offered 6 to 18 months after the initial HPV test for cervical hr-HPV positive patients was 91%, with 29 out of 32 patients returning. The positive hr-HPV result was confirmed in 25 cases. In 52% (13/25), more than one HPV type was determined by genotyping. A total of 14 different HPV-Types with oncogenic potential were detected in the cervical site (HPV 16, 18, 31, 33, 39, 45, 51, 52, 56, 58, 59, 66, 68, 73). High-grade squamous intraepithelial lesion (HSIL) was detected in four patients during follow-up in the dysplasia unit (1x CIN2, 2x CIN3, 1x VaIN3). Three out of four patients with precancerous lesions had normal pap smears (NILM).

In anal swab specimens more than one HPV genotype was detected in 52.5% of patients, and 11 different high-risk oncogenic genotypes were identified (HPV 16, 18, 31, 39, 45, 51, 52, 56, 58, 59, 68). The most common HPV-types are shown in Fig. 2.

Anal and cervical co-infection

For further investigation of co-infection in cervical hrHPV-positive patients, genotyping was performed at follow-up, whereas anal HPV testing involved genotyping at baseline and follow-up, and one positive test was considered sufficient for hrHPV positivity. All detected HPV types were included in the evaluation of co-infection, regardless of the time of examination. In patients with cervical hrHPV positivity, anal co-infection was detected in 68,8% (22/32), whereas in cervical HPV-negative patients, only 10.9% (18/165) had an anal hrHPV infection. In 18 of 23 patients, cervical and anal genotyping was available to compare HPV genotypes. Fifteen of these 18 patients were positive for more than one HPV type. There was a strong association at the HPV-specific level: 78% (14/18) of patients exhibited at least one concordant hrHPV type, while 22% (4/18) displayed different hrHPV genotypes. The highest concordance rate was found for HPV 16, with all 6 out of 6 patients (100%) showing a coinfection in the anal swab specimens.

Former world-class rowers have an elevated risk for atrial fibrillation (AF) in the years after retirement, according to an observational case-control study.

Researchers found 1 in 5 former Olympic, world, or national-level Australian rowers aged 45-80 years had the heart rhythm anomaly. The ex-rowers, who had competed for at least 10 years, were nearly seven times more likely to have been diagnosed with AF compared to a control group. During a follow-up period of around 4 years, new cases of AF were also higher among the ex-rowers (6.3% vs 2.3%), according to the researchers, who published their findings last month in the European Heart Journal.

“As a clinician, I was not surprised that rowers experienced more AF,” said André La Gerche, PhD, MD, a cardiologist and head of the Heart Exercise And Research Trials Lab at the Victor Chang Cardiac Research Institute and St Vincent’s Hospital in Melbourne, Australia, and senior author of the study. “However, I was very surprised by the magnitude of the difference. Furthermore, I learnt that the risk persists years after retirement and is not just due to genetic factors.”

The findings are “consistent with prior research demonstrating that endurance athletes — especially highly trained endurance athletes — seem to have this higher risk of AF,” said Gregory Marcus, MD, MAS, a cardiac electrophysiologist and the inaugural Endowed Professor of Atrial Fibrillation Research at the University of California, San Francisco.

“These numbers nudge me in the direction of more aggressively screening for AF specifically in masters-aged rowers, such as with the use of Holter monitors or wearable devices approved to detect AF,” said Jeffrey Hsu, MD, an assistant professor of medicine in the Division of Cardiology at the David Geffen School of Medicine at the University of California, Los Angeles.

La Gerche and his team captured data from 121 former rowers — 75% men, all White, with a median age of 62 years — who were matched with more than 11,000 control individuals from the UK Biobank who had never rowed and had varying fitness levels. The ex-rowers had similar rates of ischemic heart disease and diabetes as did the control individuals, but lower blood pressure. They also were less likely to have ever smoked.

The athletes showed persistent changes in cardiac function after retirement. Ex-rowers had larger left ventricles, lower heart rates, longer PQ intervals, and longer QT intervals compared to control individuals.

The research, “raises the question of whether certain types of intensive exercise — like elite-level competitive rowing — leads to long-lasting, perhaps even irreversible, enlargement of the cardiac chambers,” Hsu said.

Genetics factored into the risk for AF among both groups. While the prevalence of rare variants in genes associated with cardiomyopathy was low across the study, the combined risk for individual genes associated with AF was a strong predictor of the disease in both athletes (odds ratio [OR], 3.7) and nonathletes (OR, 2.0). The proportions were similar between them (P = .37), indicating genetics did not fully account for the increased risk in the ex-rowers, La Gerche said.

Marcus flagged a few factors that may have skewed the results. The former athletes tended to be tall, White, and in many cases, drank more alcohol than control individuals — all of these factors increase the risk for AF.

Because the ex-rowers volunteered for a cardiovascular study, selection bias could have skewed prevalence higher, Marcus said. After a sensitivity analysis, ex-rowers still had a 2.5-fold higher risk for AF in the case of a 100% selection bias.

La Gerche emphasized the findings shouldn’t dissuade clinicians from encouraging regular exercise or high-level sports training.

“The overall health outcomes of these rowers are generally superb,” La Gerche said. “Rather, this highlights an important ‘Achilles heel’ that requires attention and, ideally, effective prevention strategies so that sports can be enjoyed by more people, more often.”

The study was funded by the National Health and Medical Research Council. La Gerche, Hsu, and Marcus reported having no relevant financial conflicts of interest.

Brittany Vargas is a journalist covering medicine, mental health, and wellness.

Now, a study published on July 2 in Nature has uncovered compelling genomic evidence that points to air pollution—and other environmental exposures—as a potential major factor behind this growing public health concern. The study was jointly led by researchers at the University of California San Diego and the National Cancer Institute (NCI), part of the National Institutes of Health (NIH).

“We’re seeing this problematic trend that never-smokers are increasingly getting lung cancer, but we haven’t understood why,” said study co-senior author Ludmil Alexandrov, professor of bioengineering and cellular and molecular medicine at UC San Diego, and member of UC San Diego Moores Cancer Center. “Our research shows that air pollution is strongly associated with the same types of DNA mutations we typically associate with smoking.”

“This is an urgent and growing global problem that we are working to understand regarding never-smokers,” said Maria Teresa Landi, epidemiologist in the Division of Cancer Epidemiology and Genetics at the NCI and co-senior author of the study. “Most previous lung cancer studies have not separated data of smokers from non-smokers, which has limited insights into potential causes in those patients. We have designed a study to collect data from never-smokers around the world and use genomics to trace back what exposures might be causing these cancers.”

And while previous studies in the literature have shown an epidemiological link between air pollution and lung cancer in never-smokers, this new research goes further by showing a genomic link.

Mutational effects of air pollution

The team analyzed lung tumors from 871 never-smokers living in 28 regions with different levels of air pollution across Africa, Asia, Europe and North America. Using whole-genome sequencing, the researchers identified distinct patterns of DNA mutations—known as mutational signatures—that act like molecular fingerprints of past exposures.

By combining these genomic data with pollution estimates based on satellite and ground-level measurements of fine particulate matter, the researchers were able to estimate individuals’ long-term exposure to air pollution. They found that never-smokers living in more polluted environments had significantly more mutations in their lung tumors, particularly driver mutations—which directly promote cancer development—and mutational signatures linked to cancer—which serve as a record of all past mutagenic exposures. For example, these individuals had a 3.9-fold increase in a mutational signature linked to tobacco smoking and a 76% increase in another signature linked to aging.

This doesn’t mean that pollution causes a unique “air pollution mutational signature” per se, noted study co-first author Marcos Díaz-Gay, a former postdoctoral researcher in Alexandrov’s lab who is now a junior group leader at the Spanish National Cancer Research Center (CNIO) in Madrid, Spain. Rather, it increases the overall number of mutations, particularly in known pathways of DNA damage. “What we see is that air pollution is associated with an increase in somatic mutations, including those that fall under known mutational signatures attributed to tobacco smoking and aging,” said Díaz-Gay.

The researchers also noted a dose-response relationship: the more pollution someone was exposed to, the more mutations were found in their lung tumors. These tumors also had shorter telomeres—the protective caps on the ends of chromosomes—which is a sign of accelerated cellular aging.

Surprising finding from secondhand smoke exposure

In contrast, the researchers did not find a strong genetic correlation with secondhand smoke. Lung tumors of never-smokers exposed to secondhand smoke showed only a slight increase in mutations, along with shorter telomeres, but no distinct mutational signatures or driver mutations. While exposure to secondhand smoke is a known cancer risk, its mutational effect was far less pronounced than that seen with air pollution. “If there is a mutagenic effect of secondhand smoke, it may be too weak for our current tools to detect,” said study co-first author Tongwu Zhang, an Earl Stadtman Investigator in the Biostatistics Branch of the NCI. “However, its biological effects are still evident in the significant telomere shortening.”

The researchers acknowledged that their analysis could be further limited by the complexity of measuring secondhand smoke exposure. “It’s difficult to get that kind of information because it depends on various factors such as amount of time one was exposed; how far one was from exposure; and how often one shared a space with someone else who smoked, for example,” said Díaz-Gay.

Risk found from herbal medicine

In addition to air pollution, researchers identified another environmental risk: aristolochic acid, a carcinogen found in certain traditional Chinese herbal medicines. A specific mutational signature linked to aristolochic acid was found almost exclusively in lung cancer cases of never-smokers from Taiwan. Though aristolochic acid has previously been linked to bladder, gastrointestinal, kidney and liver cancers from ingestion, this is the first study to report evidence that it may contribute to lung cancer. The researchers suspect that these cases may arise from inhalation of traditional Chinese herbal medicines, but more data are needed to support their hypothesis.

“This raises new concerns about how traditional remedies might unintentionally raise cancer risk,” said Landi. “It also presents a public health opportunity for cancer prevention—particularly in Asia.”

New signature, new questions

In another intriguing discovery, the team identified a new mutational signature that appears in the lung cancers of most never-smokers but is absent in smokers. Its cause remains unknown—it did not correlate with air pollution or any other known environmental exposure. “We see it in a majority of cases in this study, but we don’t yet know what’s driving it,” said Alexandrov. “This is something entirely different, and it opens up a whole new area of investigation.”

Next steps

Moving forward, the researchers are expanding their study to include lung cancer cases of never-smokers from Latin America, the Middle East and more regions of Africa. The researchers are also turning their attention to other potential risks. One focus is on marijuana and e-cigarette use, particularly among younger people who have never smoked tobacco. The team is investigating whether these exposures may also contribute to mutational changes in lung tissue. They also aim to study other environmental risks—such as radon and asbestos—as well as gather more detailed pollution data at local and individual levels.

Reference: Díaz-Gay M, Zhang T, Hoang PH, et al. The mutagenic forces shaping the genomes of lung cancer in never smokers. Nature. 2025:1-12. doi: 10.1038/s41586-025-09219-0

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source. Our press release publishing policy can be accessed here.

Thank you. Listen to this article using the player above. ✖

In the early 2000s the U.S. Diabetes Prevention Program (DPP), a large randomized clinical trial, showed that intensive lifestyle modification was better than a medication called metformin at preventing at-risk patients from developing Type 2 diabetes.

In a newly completed follow-up study, a team of researchers including Vallabh “Raj” Shah, professor emeritus in The University of New Mexico Departments of Internal Medicine and Biochemistry & Molecular Biology at the School of Medicine, found that the health benefits from the lifestyle intervention persisted more than 20 years later.

In a paper published in The Lancet Diabetes & Endocrinology, they reported that the greatest results from both interventions were seen in the first few years of the study, and they were durable, Shah said. “The data suggests that those people who didn’t get diabetes also didn’t get diabetes after 22 years,” he said.

The DPP was launched in 1996 to compare the benefits of metformin – then newly approved by the FDA to treat Type 2 diabetes – and a lifestyle modification regimen that included exercise and a healthy diet. The study enrolled 3,234 patients with prediabetes at 30 institutions in 22 states.

The intensive lifestyle intervention reduced the development of diabetes by 24%, and metformin reduced diabetes development by 17%, according to the new study. The DPP had previously found that after the first three years of study, the lifestyle intervention of moderate weight loss and increased physical activity reduced the onset of Type 2 diabetes by 58% compared with a placebo medicine, while metformin reduced development of diabetes by 31%.

Compared with the original placebo group, the median time without diabetes was extended by three-and-a-half years in the lifestyle group and two-and-a-half years in the metformin group.

“Within three years, they had to stop the study because lifestyle was better than metformin,” Shah said. “That means lifestyle, which everybody is banking on, is more effective – that is the news.”

But because a wealth of health and biological data had already been collected for patients participating in the project, the DPP was repurposed into the DPP Outcomes Study (DPPOS), enabling researchers to follow their health outcomes in multiple domains over a period of decades, he said.

Shah has contributed to kidney disease research for more than three decades, conducting multiple studies at Zuni Pueblo and other American Indian communities in western New Mexico. He has also overseen the participation of the American Indian cohort enrolled in the DPPOS. Meanwhile, David Schade, MD, chief of the Division of Endocrinology in the UNM School of Medicine, recruited New Mexico participants in the study.

More recently, he said, DPPOS researchers have taken advantage of their large, well-documented cohort to repurpose the study to focus on diseases associated with aging, such as cancer and dementia, Shah said.

Reference: Knowler WC, Doherty L, Edelstein SL, et al. Long-term effects and effect heterogeneity of lifestyle and metformin interventions on type 2 diabetes incidence over 21 years in the US Diabetes Prevention Program randomised clinical trial. Lancet Diabetes Endocrinol. 2025;13(6):469-481. doi: 10.1016/S2213-8587(25)00022-1

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source. Our press release publishing policy can be accessed here.